Head-To-Head Survey: La Jolla Pharmaceutical (LJPC) versus Its Rivals
La Jolla Pharmaceutical (NASDAQ: LJPC) is one of 284 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare La Jolla Pharmaceutical to related businesses based on the strength of its valuation, dividends, profitability, analyst recommendations, earnings, institutional ownership and risk.
Valuation and Earnings
This table compares La Jolla Pharmaceutical and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|La Jolla Pharmaceutical||$620,000.00||-$78.18 million||-6.54|
|La Jolla Pharmaceutical Competitors||$286.20 million||$34.74 million||140.26|
La Jolla Pharmaceutical’s rivals have higher revenue and earnings than La Jolla Pharmaceutical. La Jolla Pharmaceutical is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a summary of current ratings and recommmendations for La Jolla Pharmaceutical and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|La Jolla Pharmaceutical||0||0||6||0||3.00|
|La Jolla Pharmaceutical Competitors||811||3183||11536||230||2.71|
La Jolla Pharmaceutical currently has a consensus price target of $54.60, suggesting a potential upside of 63.72%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.58%. Given La Jolla Pharmaceutical’s stronger consensus rating and higher probable upside, analysts clearly believe La Jolla Pharmaceutical is more favorable than its rivals.
Insider & Institutional Ownership
50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 25.5% of La Jolla Pharmaceutical shares are owned by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This table compares La Jolla Pharmaceutical and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|La Jolla Pharmaceutical||N/A||-88.55%||-78.19%|
|La Jolla Pharmaceutical Competitors||-5,339.09%||-435.51%||-40.49%|
Risk and Volatility
La Jolla Pharmaceutical has a beta of 1.68, suggesting that its stock price is 68% more volatile than the S&P 500. Comparatively, La Jolla Pharmaceutical’s rivals have a beta of 0.79, suggesting that their average stock price is 21% less volatile than the S&P 500.
La Jolla Pharmaceutical beats its rivals on 7 of the 12 factors compared.
La Jolla Pharmaceutical Company Profile
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH). It has initiated a Phase III trial of LJPC-501 for the treatment of CRH, called the Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS) Phase III trial. LJPC-401 is its formulation of synthetic human hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is its next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections, as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.
Receive News & Ratings for La Jolla Pharmaceutical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical Company and related companies with MarketBeat.com's FREE daily email newsletter.